

**Subject** Insulin safety net program

**Authors** Backer

**Analyst** Elisabeth Klarqvist

**Date** March 23, 2026

## Overview

The insulin safety net program was established in 2020 and consists of an urgent-need program and a continuing safety net program. Under the urgent-need program, eligible individuals who urgently need insulin may obtain a 30-day supply of insulin from pharmacies and in certain circumstances may obtain an additional 30-day supply, and insulin manufacturers must either reimburse pharmacies for insulin provided under the program or supply insulin to pharmacies on a replacement basis. Under the continuing safety net program, eligible individuals may obtain insulin through insulin manufacturer patient assistance programs. Manufacturers that provide insulin under these programs may request reimbursement from the state for the insulin provided from the insulin repayment account in the special revenue fund.

This bill adds a definition of covered insulin to the insulin safety net program and to a section establishing a registration fee for insulin manufacturers; specifies the program provides for access to covered insulin; and makes technical changes to these sections.

## Summary

Section	Description
---------	-------------

- |   |   |
|---|---|
| 1 | <b>Insulin safety net.</b><br>Amends § 13.381, subd. 20. Updates a term in section 13.381, subdivision 20, a subdivision that refers to data practices provisions in chapter 151 regarding participation in the insulin safety net program.   |
| 2 | <b>Establishment.</b><br>Amends § 151.74, subd. 1. Defines covered insulin for the insulin safety net program as a validly prescribed drug that contains insulin to treat diabetes, and specifies covered insulin does not include an insulin product labeled as only for use via intravenous infusion. Strikes language in the definition of manufacturer referring to |

Section	Description
	the manufacture of insulin that is self-administered on an outpatient basis. Requires insulin manufacturers to establish procedures to make covered insulin (rather than insulin as in current law) available under the urgent need program and the continuing safety net program. Updates a term, from insulin to covered insulin, in this subdivision to conform with the new definition, and strikes an unnecessary date.
3	<b>Eligibility for urgent-need safety net program.</b> Amends § 151.74, subd. 2. In a subdivision specifying eligibility of individuals to receive an urgently needed supply of insulin, updates a term to conform with the definition added in subdivision 1.
4	<b>Access to urgent-need covered insulin.</b> Amends § 151.74, subd. 3. In a subdivision specifying the process to apply for an urgently needed supply of insulin, updates a term to conform with the definition added in subdivision 1.
5	<b>Continuing safety net program; general.</b> Amends § 151.74, subd. 4. In a subdivision governing patient eligibility for manufacturer patient assistance programs to obtain a continuing supply of insulin, updates a term to conform with a definition added in subdivision 1.
6	<b>Continuing safety net program; manufacturer's responsibilities.</b> Amends § 151.74, subd. 5. In a subdivision governing manufacturer responsibilities upon receipt of a patient application for the manufacturer's patient assistance program, updates a term to conform with a definition added in subdivision 1.
7	<b>Continuing safety net program; process.</b> Amends § 151.74, subd. 6. In a subdivision specifying the process through which a patient participating in a manufacturer's patient assistance program obtains insulin under the program, updates a term to conform with a definition added in subdivision 1.
8	<b>Board of Pharmacy and MNsure responsibilities.</b> Amends § 151.74, subd. 7. In a subdivision specifying duties of the Board of Pharmacy and MNsure regarding the urgent-need program and manufacturer patient assistance programs, updates a term to conform with a definition added in subdivision 1.

<b>Section</b>	<b>Description</b>
9	<p><b>Additional 30-day urgent-need covered insulin supply.</b></p> <p>Amends § 151.74, subd. 9. In a subdivision specifying circumstances in which an individual may access an additional 30-day supply of urgent-need insulin, updates a term to conform with a definition added in subdivision 1.</p>
10	<p><b>Penalty.</b></p> <p>Amends § 151.74, subd. 10. In a subdivision establishing penalties against a manufacturer that fails to comply with this section, changes the name of the account into which assessed penalties must be deposited, from the insulin assistance account to the covered insulin assistance account.</p>
11	<p><b>Data.</b></p> <p>Amends § 151.74, subd. 11. In a subdivision classifying data held by specified government entities or trained navigators related to the urgent-need program or a manufacturer's patient assistance program, updates a term to conform with a definition added in subdivision 1.</p>
12	<p><b>Reports.</b></p> <p>Amends § 151.74, subd. 13. In a subdivision establishing requirements for reports by manufacturers to the Board of Pharmacy and reports by the board to certain members of the legislature, strikes dates that have passed and updates a term to conform with a definition added in subdivision 1.</p>
13	<p><b>Program review; legislative auditor.</b></p> <p>Amends § 151.74, subd. 14. In a subdivision requesting the legislative auditor to review aspects of the urgent-need program and manufacturer assistance programs, updates a term to conform with a definition added in subdivision 1.</p>
14	<p><b>Definitions.</b></p> <p>Amends § 151.741, subd. 1. Adds a definition of covered insulin to a section governing the insulin manufacturer registration fee assessed on insulin manufacturers and updates a term to conform with the new definition.</p>
15	<p><b>Assessment of registration fee.</b></p> <p>Amends § 151.741, subd. 2. In a subdivision governing assessment of a registration fee on insulin manufacturers, updates a term to conform with a definition added in subdivision 1.</p>

Section	Description
16	<b>Insulin repayment account; annual transfer from health care access fund.</b> Amends § 151.741, subd. 5. In a subdivision governing the process to reimburse manufacturers for insulin provided under the insulin safety net program, updates a term to conform with a definition added in subdivision 1.
17	<b>Repealer.</b> Repeals § 151.74, subd. 15 (requiring the commissioner of health to develop and conduct surveys of program participants and pharmacies on the insulin safety net program; results of these surveys were required to be reported to the legislature in 2022).



**MN HOUSE  
RESEARCH**

*Minnesota House Research Department provides nonpartisan legislative, research, and legal services to the Minnesota House of Representatives. This document can be provided in other formats.*

[www.house.mn.gov/hrd](http://www.house.mn.gov/hrd) | 651-296-6753 | Third Floor, Centennial Office Building, St. Paul, MN 55155